ArticleCommunications medicine2024
Mendelian randomization study of the relationship between blood and urine biomarkers and schizophrenia in the UK Biobank cohort.
Article in Communications medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 6 citations in OpenAlex.
- Trial
- Genetic evidence for causal relationship between general cognition and treatment resistance in schizophrenia.Translational psychiatry · 2026Article
- The role of high-amplitude bursts of high-gamma activity in naturalistic speech and music listening.Imaging neuroscience (Cambridge, Mass.) · 2026Article
- MR-EILLS: an invariance-based Mendelian randomization method integrating multiple heterogeneous GWAS summary datasets.Nature communications · 2025Article
- Body fluid biomarkers and psychosis risk in The Accelerating Medicines Partnership® Schizophrenia Program: design considerations.Schizophrenia (Heidelberg, Germany) · 2025Article
- Relationship between renal function and cognitive impairment in patients with stable schizophrenia: a multicenter cross-sectional study.BMC psychiatry · 2025Article
- Mendelian randomization study of the relationship between blood and urine biomarkers and schizophrenia in the UK Biobank cohort.Communications medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe identification of suitable biomarkers is of crucial clinical importance for the early diagnosis of treatment-resistant schizophrenia (TRS). This study aims to comprehensively analyze the association between TRS and blood and urine biomarkers.
methodsCandidate TRS-related single nucleotide polymorphisms (SNPs) were obtained from a recent genome-wide association study. The UK Biobank cohort, comprising 376,807 subjects with blood and urine biomarker testing data, was used to calculate the polygenic risk score (PRS) for TRS. Pearson correlation analyses were performed to evaluate the correlation between TRS PRS and each of the biomarkers, using calculated TRS PRS as the instrumental variables. Bidirectional two-sample Mendelian randomization (MR) was used to assess potential causal associations between candidate biomarkers with TRS.
resultsHere we identify a significant association between TRS PRS and phosphate (r = 0.007, P = 1.96 × 10
conclusionsOur findings provide insights into the roles of blood and urine biomarkers in the early detection and treatment of TRS.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.